Vancouver, British Columbia-An $855 million deal will unite verteporfin (Visudyne) developer QLT Inc. and Atrix Laboratories Inc. to build QLT's business and accelerate strategic initiatives.
ChatGPT may have a future use in glaucoma
Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics
Therapeutic in development to take on diabetic macular edema
Mastering the New Treatment Paradigm in Geographic Atrophy – From Detection to Intervention
Ocugen completes dosing in subjects with GA secondary to dAMD in Phase 1/2 ArMaDa clinical trial of OCU410
Stress resilience–enhancing drugs: New class of small molecules holds promise